Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

- PMLiVE

Astellas signs up to immuno-oncology deal

Japanese firm the latest pharma company to buy into the next-gen cancer therapy area

- PMLiVE

Creston acquires How Splendid

Agency looks to bolster its digital offering with new buy

- PMLiVE

Reaching beyond adherence

To truly achieve patient engagement you also need to engage those influencing them

Teva Pharma logo

Teva slapped with $512m fine on pay-for-delay deal

Israeli firm pays out to settle claims it hindered use of generic Provigil

Making a difference with mobile health

Sanofi talks to PME about its latest mHealth initiative and tackling the diabetes epidemic

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

- PMLiVE

Cello Health Consulting appoints Beverly Hope as senior consultant

She brings experience from PPD and GSK to the role

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

- PMLiVE

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

- PMLiVE

MedImmune and Immunocore to join on melanoma trials

Will trial MEDI4736 in combination with tremelimumab

- PMLiVE

Listen? Do you want to know a secret?

Social media listening is currently trending, but is it ‘hear’ to stay for pharma?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links